RNA interference to target lipid disorders

Current Opinion in Lipidology

Volumn 19, Issue 3, 2008, Pages 285-288

  Rondinone, Cristina M ^a,b  

^a HOFFMANN LA ROCHE INC   (United States)

^b Hoffman La Roche Department of Metabolic Diseases   (United States)

Author keywords

Cholesterol; Lipid disorders; Lipogenesis; RNA interference

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN B; CHOLESTEROL; LIPID; RNA; SHORT HAIRPIN RNA;

CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DOWN REGULATION; DRUG TARGETING; DYSLIPIDEMIA; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; IN VIVO CULTURE; JEJUNUM; LIPID BLOOD LEVEL; LIPOGENESIS; LIVER; MAMMAL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RNA INTERFERENCE; TISSUE SPECIFICITY; VALIDATION STUDY;

DYSLIPIDEMIAS; HUMANS; LIPOGENESIS; LIVER; RNA INTERFERENCE;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

EID: 43249127586     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282ff861e     Document Type: Review

References (29)

1. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431:343-349.
2. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409:363-366.
3. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101:25-33.
4. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature 2000; 404:293-296.
5. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 2001; 107:309-321.
6. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200.
7. Tijsterman M, Ketting RF, Plasterk RH. The genetics of RNA silencing. Annu Rev Genet 2002; 36:489-519.
8. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4:457-467.
9. Hutvagner G, Zamore PA. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002; 297:2056-2060.
10. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110:563-574.
11. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during nonalcoholic fatty liver disease. Diabetes Metab 2003; 29:478-485.
12. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77:43-50.
13. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115:1343-1351.
14. Taniguchi CM, Ueki K, Kahn CR. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005; 115:718-727.
15. Yang R, Wilcox DM, Haasch DL, et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem 2007; 282:22765-22774. This article surprisingly shows the effect of JNK1 on plasma triglyceride levels.
16. Gomez-Valades AG, Vidal-Alabro A, Molas M, et al. Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. Mol Ther 2006; 13:401-410.
17. Xu H, Wilcox D, Nguyen P, et al. Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. Biochem Biophys Res Commun 2006; 349:439-448.
18. Hammond LE, Neschen S, Romanelli AJ. Mitochondrial glycerol-3-phosphate acyltransferase-1 is essential in liver for the metabolism of excess acyl-CoAs. J Biol Chem 2005; 280:25629-25636.
19. Dentin R, Pégorier JP, Benhamed F, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004; 279:20314-20326.
20. Izuka K, Bruick RK, Liang G, et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A 2004; 101:7281-7286.
21. Dentin R, Benhamed F, Hainault I, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 2006; 55:2159-2170. This article shows that ChREBP is central for the regulation of lipogenesis in vivo and plays a determinant role in the development of the hepatic steatosis and of insulin resistance.
22. Ragozin S, Niemeier A, Laatsch A, et al. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol 2005; 25:1433.
23. McNeish J, Aiello RJ, Guyot D, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A 2000; 97:4245-4250.
24. Burnett JR, Barrett PH. Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit Rev Clin Lab Sci 2002; 39:89-137.
25. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
26. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-178.
27. Farese RV Jr, Ruland SL, Flynn LM, et al. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc Natl Acad Sci U S A 1995; 92:1774-1778.
28. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in nonhuman primates. Nature 2006; 441:111-114. This article highlights the potential for therapeutic gene silencing using systemic RNAi in nonhuman primates.
29. Rondinone CM. Therapeutic potential of RNAi in metabolic diseases. BioTechniques 2006; 40:S31-S36. This is a review highlighting the potential of RNAi technology for therapeutics.